Stryker (SYK) AI Stock Analysis

• Market Cap: $130.02B
• Dividend Yield: 0.95%
• Average Volume (3M): 2.08M
• Price to Earnings (P/E): 41.4
• Beta (1Y): 0.69
• Revenue Growth: 10.95%
• EPS Growth: -18.32%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 4.47
• Shares Outstanding: 382,688,700
• 10 Day Avg. Volume: 2,372,881
• 30 Day Avg. Volume: 2,076,997
• PEG Ratio: 5.16
• Price to Book (P/B): 5.99
• Price to Sales (P/S): 5.35
• P/FCF Ratio: 31.36
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 5.61
• Enterprise Value/Gross Profit: 8.83
• Enterprise Value/Ebitda: 25.23
• 1Y Price Target: $431.35
• Price Target Upside: 24.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 22
• EPS Forecast (FY): 15.01
• Revenue Forecast (FY): $27.34B

• Rating: 67 Neutral
• Price Target: $366.00 ▲(5.84% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

SYK scores well on core fundamentals and management’s constructive 2026 outlook, but the overall score is held back by weak current technical momentum, a premium valuation (high P/E, modest yield), and added near-term uncertainty from the cybersecurity-related operational disruption.

Positive Factors

Consistent revenue growth

Stryker’s multi-year revenue expansion to $25.1B reflects durable demand across orthopaedics, MedSurg and neurotechnology. Consistent growth supports scale advantages, cross-selling, R&D funding and less sensitivity to single-market dips, underpinning sustainable top-line momentum.

Robotics installed base leadership

A >3,000 Mako installed base with rising utilization creates a sticky revenue stream from consumables, services and upgrades. Robotics leadership strengthens clinical preference, raises switching costs and supports long-term margin expansion through recurring, higher-margin aftermarket sales.

Strong cash generation & improving leverage

Robust cash flow and declining leverage provide financial flexibility for R&D, capital investment and M&A. Consistent FCF (approx. 70–80% conversion targets) supports reinvestment and shareholder returns while cushioning the business against cyclical capital spending volatility.

Negative Factors

Tariff headwind (~$400M)

A near-term $400M tariff hit materially pressures 2026 margins and operating income, forcing either cost absorption or price recovery. Persistent tariff exposure can erode competitiveness, squeeze reinvestment capacity and complicate margin guidance and planning for the year.

Cybersecurity operational risk

A major IT disruption that impairs order processing and manufacturing threatens execution reliability, customer service and revenue recognition. Remediation and hardened controls can be costly, raise regulatory scrutiny, and create persistent operational risk until fully addressed.

Absolute debt level & margin drift

Although leverage has improved, a ~$14.9B debt stock with rising interest expense limits strategic flexibility and increases fixed costs. Coupled with modest margin erosion versus 2023, this reduces room for error on growth or cost shocks and constrains aggressive capital allocation choices.

Stryker Business Overview & Revenue Model

Company Description

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

How the Company Makes Money

Stryker makes money primarily by selling medical devices, implants, capital equipment, and related consumables and services to healthcare providers. Key revenue streams 1) Implantable and procedure-based products (recurring, volume-driven): A large portion of revenue comes from orthopaedic implants and other procedure-dependent devices (e.g., hip and knee replacements and associated instrumentation). These products generate revenue each time a procedure is performed, and demand is tied to surgical volumes, demographics (e.g., aging populations), and hospital/provider preference. 2) Surgical capital equipment (periodic, budget-driven) plus recurring disposables: Stryker also sells higher-priced capital equipment used in operating rooms and hospitals (e.g., surgical systems and other durable devices). While capital sales can be more cyclical and influenced by hospital budgeting, they often create an installed base that drives follow-on revenue from single-use disposables, accessories, and replacement parts used in ongoing procedures. 3) Service, maintenance, and support: For certain equipment and systems, Stryker earns revenue from service contracts, maintenance, repairs, and other support offerings. These can provide more predictable revenue tied to the installed base. Commercial model and pricing dynamics - Sales are largely B2B, with purchasing decisions influenced by value analysis committees, group purchasing organizations, physician preference, clinical outcomes, and total cost of ownership. Revenue is typically realized through product sales under negotiated contracts, with pricing shaped by competition, reimbursement, and hospital procurement practices. Strategic factors that support earnings - Portfolio breadth across multiple hospital departments can support cross-selling and long-term customer relationships. - An installed base of equipment can support recurring consumable and service revenue. - Acquisitions have historically been an important component of Stryker’s growth strategy, expanding product categories and adding revenue sources. Significant partnerships: null

Stryker Financial Statement Overview

Summary

Fundamentals are strong: steady revenue expansion to $25.1B (2025), solid industry profitability (gross margin ~61%, net margin ~13%), improving leverage (debt-to-equity down to ~0.66), and consistently strong free cash flow ($4.3B in 2025). Key offsets are modest margin compression vs. 2023 and a still-meaningful absolute debt load (~$14.9B).

Income Statement

Revenue has expanded steadily from $14.4B (2020) to $25.1B (2025), with growth positive in every year after 2020. Profitability is strong for the industry, with 2025 gross margin ~61% and net margin ~13%. However, margins have drifted down versus 2023 (net margin ~15% and higher operating profitability), suggesting some mix, cost, or investment pressure even as scale improves.

Balance Sheet

Leverage is moderate and improving: debt-to-equity declined from ~1.01 (2020) to ~0.66 (2025) while equity rose to $22.4B, indicating strengthening capitalization. Returns on equity remain solid (~14–17% across the period), though down from the 2023 peak. The main watch item is still absolute debt (~$14.9B in 2025), which, while manageable, leaves less flexibility if operating conditions weaken.

Cash Flow

Cash generation is healthy and improving, with operating cash flow rising from $3.3B (2020) to $5.0B (2025) and free cash flow to $4.3B. Free cash flow consistently tracks net income well (roughly ~0.78–0.85x), supporting earnings quality. The key weakness is volatility in year-to-year free cash flow growth (notably a decline in 2022), and the cash conversion profile suggests some ongoing working-capital/cash timing noise despite strong overall generation.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	25.12B	22.59B	20.50B	18.45B	17.11B
Gross Profit	16.07B	13.98B	12.49B	11.04B	10.71B
EBITDA	6.31B	4.94B	5.06B	4.02B	3.61B
Net Income	3.25B	2.99B	3.17B	2.36B	1.99B
Balance Sheet
Total Assets	47.84B	42.97B	39.91B	36.88B	34.63B
Cash, Cash Equivalents and Short-Term Investments	4.10B	4.49B	3.05B	1.93B	3.02B
Total Debt	14.86B	14.12B	13.49B	13.53B	12.90B
Total Liabilities	25.42B	22.34B	21.32B	20.27B	19.75B
Stockholders Equity	22.42B	20.63B	18.59B	16.62B	14.88B
Cash Flow
Free Cash Flow	4.28B	3.49B	3.14B	2.04B	2.74B
Operating Cash Flow	5.04B	4.24B	3.71B	2.62B	3.26B
Investing Cash Flow	-4.87B	-3.00B	-962.00M	-2.92B	-859.00M
Financing Cash Flow	113.00M	-525.00M	-1.59B	-749.00M	-2.37B

Stryker Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 345.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Negative. The current price of 345.81 is below the 20-day moving average (MA) of 366.05, below the 50-day MA of 363.96, and below the 200-day MA of 372.47, indicating a bearish trend. The MACD of -7.21 indicates Positive momentum. The RSI at 33.92 is Neutral, neither overbought nor oversold. The STOCH value of 38.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYK.

Stryker Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EW	75 Outperform	$47.89B	46.44	10.39%	―	0.19%	65.58%
MDT	71 Outperform	$111.53B	28.29	9.54%	2.76%	5.34%	13.15%
BSX	68 Neutral	$103.71B	48.91	12.53%	―	21.62%	54.80%
SYK	67 Neutral	$130.02B	41.38	15.04%	0.95%	10.95%	-18.32%
ZBH	65 Neutral	$17.58B	31.78	5.60%	1.05%	5.47%	-23.03%
ABT	62 Neutral	$186.26B	33.55	12.89%	1.88%	6.37%	142.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Stryker Corporate Events

Stryker Reports Cybersecurity Incident Disrupting Global IT Systems

On March 11, 2026, Stryker Corporation identified a cybersecurity incident that disrupted its global Microsoft-based information technology environment, and on March 12, 2026, Chief Information Security Officer Dave Nathans briefed customers and cybersecurity professionals on the situation. The company reported ongoing disruptions to order processing, manufacturing and shipping but said it does not believe patient-related services or connected products have been affected, while its investigation continues and the full operational and financial impact remains unknown.

The most recent analyst rating on (SYK) stock is a Hold with a $370.00 price target. To see the full list of analyst forecasts on Stryker stock, see the SYK Stock Forecast page.

Stryker Investigates Cybersecurity Incident Disrupting IT Systems

On March 11, 2026, Stryker Corporation identified a cybersecurity incident that disrupted its global Microsoft information technology environment and affected access to certain systems and business applications. The company activated its cybersecurity response plan, engaged external experts and implemented business continuity measures to support customers and partners, but the full extent of operational and financial impacts and the timeline for complete system restoration remain uncertain, and Stryker has not yet determined whether the incident will be materially significant.

The most recent analyst rating on (SYK) stock is a Buy with a $420.00 price target. To see the full list of analyst forecasts on Stryker stock, see the SYK Stock Forecast page.